Skip to content
2000
Volume 23, Issue 38
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Scientific community is striving to understand the role of heterocycles and fused heterocycles in drug discovery programme due to its impact on multi-drug resistance (MDR) of anticancer drugs. Architecting of various scaffolds for cancer treatment has become gradually increased in many years. Till now there is no treatment which is so proficient that it can cure the cancer from the roots. Hence, it is very necessary to design novel anticancer agents with minimum side effects. Synthesis of hybrids from natural leads is one of the rationale approaches in medicinal chemistry. It remains a big challenge to invent new efficient drugs to beat cancer. The design and synthesis of fused molecules as anticancer agents is one of the great innovations of modern era. In drug discovery archetype, a variety of heterocycles have been considered for the development of novel lead compounds. This article presents some recent advancements in the field of anticancer heterocyclic agents all around the world and also attracted the structure activity relationship along with the structure of the most promising molecules along with IC50 values against various human cancer cell lines.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867323666160809093930
2016-11-01
2025-05-12
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867323666160809093930
Loading

  • Article Type:
    Research Article
Keyword(s): Cytotoxic Agents; Fusion; IC50; N-Heterocycles; Natural leads; Oxadiazoles
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test